| RAS protein activator-like 2 (RASAL2) initiates peritubular capillary rarefaction in hypoxic renal interstitial fibrosis. | RAS protein activator-like 2 (RASAL2) initiates peritubular capillary rarefaction in hypoxic renal interstitial fibrosis.
Zhang Y, Yang Y, Hu X, Wei B, Shen Q, Shi C, Chen P. | 07/9/2024 |
| CAMSAP2 enhances lung cancer cell metastasis by mediating RASAL2 degradation. | CAMSAP2 enhances lung cancer cell metastasis by mediating RASAL2 degradation.
Singharajkomron N, Yodsurang V, Limprasutr V, Wattanathamsan O, Iksen I, Hayakawa Y, Pongrakhananon V. | 01/28/2024 |
| Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer. | Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.
Wills C, Watts K, Maughan TS, Fisher D, Al-Tassan NA, Houlston RS, Escott-Price V, Cheadle JP., Free PMC Article | 04/12/2023 |
| RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. | RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma.
Yue Y, Wu K, Qian W, Zhu Z, Zhang S, Zhang W, Zhang W, Wu S, Li L, Wu Z, Ma Q, Xie K, Wang Z., Free PMC Article | 07/23/2022 |
| PRKAA/AMPKalpha phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy. | PRKAA/AMPKα phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy.
Bao Y, Qian C, Liu MY, Jiang F, Jiang X, Liu H, Zhang Z, Sun F, Fu N, Hou Z, Ke Y, Li Y, Qian ZM., Free PMC Article | 03/26/2022 |
| Inhibition of Ras protein activator like 2 produces antitumor effects in gastric cancer via the suppression of YAP1 activation. | Inhibition of Ras protein activator like 2 produces antitumor effects in gastric cancer via the suppression of YAP1 activation.
Hu Y, Zhang P, Shi Y, Dong X, Wu Y, Dong D, Li E, Fan Y. | 02/5/2022 |
| Low Expression of Rasal2 Promotes Non-small Cell Lung Cancer Metastasis through Ras/ERK Pathway. | Low Expression of Rasal2 Promotes Non-small Cell Lung Cancer Metastasis through Ras/ERK Pathway.
Fan D, Yu S, Yang Y, Qu S. | 01/1/2022 |
| miR6543p suppresses cell viability and promotes apoptosis by targeting RASAL2 in nonsmallcell lung cancer. | miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer.
Xiong J, Xing S, Dong Z, Niu L, Xu Q, Li Y, Liu P, Yang P., Free PMC Article | 05/8/2021 |
| the phosphorylation of Rasal2 at S237 in PH domain facilitates tumour progression. | Phosphorylated Rasal2 facilitates breast cancer progression.
Wang X, Qian C, Yang Y, Liu MY, Ke Y, Qian ZM., Free PMC Article | 05/2/2020 |
| These findings revealed a new mechanism of Rasal2 in the regulation of breast cancer cell proliferation via autophagy-exosome-mediated pathway. | Rasal2 suppresses breast cancer cell proliferation modulated by secretory autophagy.
Wang X, Yin X, Yang Y. | 01/18/2020 |
| IPO5 is an oncogene involved in CRC cell proliferation and migration. This highlights the significance of IPO5 in 5-fluorouracil-resistant CRC cells. The oncogenic function of IPO5 was mediated by promoting RAS signalling by increasing the nuclear translocation of RASAL2 | IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation.
Zhang W, Lu Y, Li X, Zhang J, Lin W, Zhang W, Zheng L, Li X., Free PMC Article | 12/21/2019 |
| RASAL2 could activate GSK3beta by reducing Ser9 phosphorylation. | The expression and function of RASAL2 in renal cell carcinoma angiogenesis.
Hui K, Yue Y, Wu S, Gu Y, Guan B, Wang X, Hsieh JT, Chang LS, He D, Wu K., Free PMC Article | 11/23/2019 |
| The authors discovered that RASAL2, a RAS GTPase activating protein, could inhibit bladder cancer angiogenesis based on shRNA/siRNA knockdown or ectopic cDNA expression experiments. | RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer.
Hui K, Wu S, Yue Y, Gu Y, Guan B, Wang X, Hsieh JT, Chang LS, He D, Wu K. | 09/21/2019 |
| Study identified copy number gains and upregulation of RASAL2 in metastatic colorectal cancer (CRC). Upregulation of RASAL2 protein expression was associated with poor prognosis and metastasis. Functional studies revealed that RASAL2 promoted tumor progression in CRC cells. Its knockdown promoted YAP1 phosphorylation, cytoplasm retention and ubiquitination, therefore activating LATS2/YAP1 axis of hippo pathway. | RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
Pan Y, Tong JHM, Lung RWM, Kang W, Kwan JSH, Chak WP, Tin KY, Chung LY, Wu F, Ng SSM, Mak TWC, Yu J, Lo KW, Chan AWH, To KF., Free PMC Article | 03/23/2019 |
| Furthermore, overexpression of miR-203 exhibited a similar effect to RASAL2 knockdown in hepatocellular carcinoma (HCC) cells. These results indicated that RASAL2 serves a tumor oncogenic role in HCC and may be considered a potential target in HCC. | Upregulation of RASAL2 promotes proliferation and metastasis, and is targeted by miR-203 in hepatocellular carcinoma.
Fang JF, Zhao HP, Wang ZF, Zheng SS. | 02/17/2018 |
| Study shows that up to 62% of luminal B cancers have lost expression of at least one of the DAB2IP and RASAL2 genes. However, the tumors that have lost both genes frequently present as advanced disease and are more likely to recur. Importantly, the report provide evidence that DAB2IP and RASAL2 can individually function as tumor suppressors in breast cancer. | Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.
Olsen SN, Wronski A, Castaño Z, Dake B, Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, Loda M, Welm A, Partridge AH, McAllister SS, Kuperwasser C, Cichowski K., Free PMC Article | 11/4/2017 |
| RASAL2 could inhibit BCa tumorigenesis. | RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.
Hui K, Gao Y, Huang J, Xu S, Wang B, Zeng J, Fan J, Wang X, Yue Y, Wu S, Hsieh JT, He D, Wu K., Free PMC Article | 11/4/2017 |
| these results demonstrated that miRNA-136 was a key anti-invasive miRNA and further confirmed the oncogenic role of RASAL2 in triple-negative breast cancer. | miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer.
Yan M, Li X, Tong D, Han C, Zhao R, He Y, Jin X., Free PMC Article | 03/18/2017 |
| High RASAL2 expression is associated with liver cancer. | Genome-wide study of hypomethylated and induced genes in patients with liver cancer unravels novel anticancer targets.
Stefanska B, Cheishvili D, Suderman M, Arakelian A, Huang J, Hallett M, Han ZG, Al-Mahtab M, Akbar SM, Khan WA, Raqib R, Tanvir I, Khan HA, Rabbani SA, Szyf M. | 10/17/2015 |
| these results indicate that activation of a RASAL2/ARHGAP24/RAC1 module contributes to TNBC tumorigenesis and identify a context-dependent role of RASAL2 in breast cancer. | RASAL2 activates RAC1 to promote triple-negative breast cancer progression.
Feng M, Bao Y, Li Z, Li J, Gong M, Lam S, Wang J, Marzese DM, Donovan N, Tan EY, Hoon DS, Yu Q., Free PMC Article | 07/25/2015 |
| Results implicate RASAL2 as an EMT regulator and tumor suppressor in ovarian cancer, and down-regulation of RASAL2 promotes ovarian cancer progression. | RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis.
Huang Y, Zhao M, Xu H, Wang K, Fu Z, Jiang Y, Yao Z., Free PMC Article | 06/6/2015 |
| the down-regulation of RASAL2 promotes metastatic progression of lung adenocarcinoma | RASAL2 promotes lung cancer metastasis through epithelial-mesenchymal transition.
Li N, Li S. | 02/14/2015 |
| The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. | The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.
McLaughlin SK, Olsen SN, Dake B, De Raedt T, Lim E, Bronson RT, Beroukhim R, Polyak K, Brown M, Kuperwasser C, Cichowski K., Free PMC Article | 12/14/2013 |
| RASAL2 was identified as an ECT2-interacting protein that regulates RHO activity in astrocytoma cells. | ECT2 and RASAL2 mediate mesenchymal-amoeboid transition in human astrocytoma cells.
Weeks A, Okolowsky N, Golbourn B, Ivanchuk S, Smith C, Rutka JT. | 12/8/2012 |
| Observational study of gene-disease association. (HuGE Navigator) | Analyses of shared genetic factors between asthma and obesity in children.
Melén E, Himes BE, Brehm JM, Boutaoui N, Klanderman BJ, Sylvia JS, Lasky-Su J., Free PMC Article | 12/5/2010 |